Trzaskos J M, Favata M F, Fischer R T, Stam S H
J Biol Chem. 1987 Sep 5;262(25):12261-8.
Biphasic modulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) has been demonstrated in primary hepatocyte cultures treated with the lanosterol 14 alpha-methyl demethylase inhibitor miconazole. At concentrations of the drug which lead to suppressed levels of reductase activity, the appearance of a polar, mevalonate-derived sterol is noted. Cochromatography of the identified sterol with 3 beta-hydroxylanost-8-en-32-aldehyde tentatively identified the metabolite as a lanosterol 14 alpha-methyl demethylation intermediate. Subsequent isolation and characterization of the metabolite by gas chromatography/mass spectroscopy confirmed this structural assignment. When the lanosterol 14 alpha-methyl demethylase-deficient mutant, AR45, was treated with authentic metabolite, a suppression of HMG-CoA reductase was observed. These results demonstrate that metabolism of the oxygenated biosynthetic intermediate is not required to suppress reductase activity. The results also strongly support the hypothesis that oxygenated 14 alpha-methyl demethylase intermediates are endogenously generated modulators of HMG-CoA reductase activity.
在用羊毛甾醇14α-甲基脱甲基酶抑制剂咪康唑处理的原代肝细胞培养物中,已证实3-羟基-3-甲基戊二酰辅酶A还原酶(HMG-CoA还原酶)存在双相调节。在导致还原酶活性水平受到抑制的药物浓度下,会观察到一种极性的、由甲羟戊酸衍生的甾醇出现。将鉴定出的甾醇与3β-羟基羊毛甾-8-烯-32-醛进行共色谱分析,初步确定该代谢物为羊毛甾醇14α-甲基脱甲基中间体。随后通过气相色谱/质谱对该代谢物进行分离和表征,证实了这一结构归属。当用真实的代谢物处理羊毛甾醇14α-甲基脱甲基酶缺陷型突变体AR45时,观察到HMG-CoA还原酶受到抑制。这些结果表明,抑制还原酶活性并不需要氧化生物合成中间体的代谢。这些结果也有力地支持了这样一种假说,即氧化的14α-甲基脱甲基酶中间体是HMG-CoA还原酶活性的内源性调节剂。